p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Martin Köbel¹, Eun-Young Kang¹, Ashley Weir^{2

3

4}, Peter F Rambau^{1

5}, Cheng-Han Lee⁶, Gregg S Nelson⁷, Prafull Ghatage⁷, Nicola S Meagher^{2

8}, Marjorie J Riggan⁹, Jennifer Alsop¹⁰, Michael S Anglesio^{11

12}, Matthias W Beckmann¹³, Christiani Bisinotto¹⁴, Michelle Boisen¹⁵, Jessica Boros^{16

17

18}, Alison H Brand^{17

18}, Angela Brooks-Wilson¹⁹, Michael E Carney²⁰, Penny Coulson²¹, Madeleine Courtney-Brooks¹⁵, Kara L Cushing-Haugen²², Cezary Cybulski²³, Suha Deen²⁴, Mona A El-Bahrawy²⁵, Esther Elishaev²⁶, Ramona Erber²⁷, Sian Fereday^{28

29}; AOCS Group^{16

28

30}; Anna Fischer³¹, Simon A Gayther³², Arantzazu Barquin-Garcia³³, Aleksandra Gentry-Maharaj³⁴, C Blake Gilks³⁵, Helena Gronwald³⁶, Marcel Grube³⁷, Paul R Harnett^{18

38}, Holly R Harris^{22

39}, Andreas D Hartkopf^{37

40}, Arndt Hartmann²⁷, Alexander Hein¹³, Joy Hendley²⁸, Brenda Y Hernandez⁴¹, Yajue Huang⁴², Anna Jakubowska^{23

43}, Mercedes Jimenez-Linan⁴⁴, Michael E Jones²¹, Catherine J Kennedy^{16

17

18}, Tomasz Kluz⁴⁵, Jennifer M Koziak⁴⁶, Jaime Lesnock¹⁵, Jenny Lester⁴⁷, Jan Lubiński²³, Teri A Longacre⁴⁸, Maria Lycke⁴⁹, Constantina Mateoiu⁵⁰, Bryan M McCauley⁵¹, Valerie McGuire⁵², Britta Ney³¹, Alexander Olawaiye¹⁵, Sandra Orsulic⁴⁷, Ana Osorio^{53

54}, Luis Paz-Ares^{55

56}, Teresa Ramón Y Cajal⁵⁷, Joseph H Rothstein^{58

59}, Matthias Ruebner¹³, Minouk J Schoemaker²¹, Mitul Shah¹⁰, Raghwa Sharma⁶⁰, Mark E Sherman⁶¹, Yurii B Shvetsov⁴¹, Naveena Singh³⁵, Helen Steed^{62

63}, Sarah J Storr⁶⁴, Aline Talhouk^{11

12}, Nadia Traficante^{28

29}, Chen Wang⁶⁵, Alice S Whittemore^{52

66}, Martin Widschwendter⁶⁷, Lynne R Wilkens⁴¹, Stacey J Winham⁶⁵, Javier Benitez^{54

68}, Andrew Berchuck⁹, David D Bowtell^{28

29}, Francisco J Candido Dos Reis¹⁴, Ian Campbell^{28

29}, Linda S Cook^{69

70}, Anna DeFazio^{8

16

17

18}, Jennifer A Doherty⁷¹, Peter A Fasching¹³, Renée T Fortner^{72

73}, María J García⁷⁴, Marc T Goodman⁷⁵, Ellen L Goode⁵¹, Jacek Gronwald²³, David G Huntsman^{11

76}, Beth Y Karlan⁴⁷, Linda E Kelemen⁷⁷, Stefan Kommoss³⁷, Nhu D Le⁷⁸, Stewart G Martin⁶⁴, Usha Menon³⁴, Francesmary Modugno^{15

79

80}, Paul Dp Pharoah^{10

81

82}, Joellen M Schildkraut⁸³, Weiva Sieh^{58

59}, Annette Staebler³¹, Karin Sundfeldt⁸⁴, Anthony J Swerdlow^{21

85}, Susan J Ramus^{2

3}, James D Brenton⁸⁶

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
² School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
³ Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
⁴ The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
⁵ Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania.
⁶ Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.
⁷ Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁸ The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
⁹ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
¹⁰ Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
¹¹ Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
¹² British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, BC, Canada.
¹³ Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
¹⁴ Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
¹⁵ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
¹⁶ Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
¹⁷ Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
¹⁸ Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.
¹⁹ Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
²⁰ Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
²¹ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
²² Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
²³ Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
²⁴ Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.
²⁵ Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK.
²⁶ Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
²⁷ Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
²⁸ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
²⁹ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
³⁰ QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
³¹ Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
³² Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³³ HM Sanchinarro Centro Integral Oncológico Clara Campal, University Hospital, Madrid, Spain.
³⁴ MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
³⁵ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
³⁶ Department of Propaedeutics, Physical Diagnostics and Dental Physiotherapy, Pomeranian Medical University, Szczecin, Poland.
³⁷ Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
³⁸ Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.
³⁹ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁴⁰ Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany.
⁴¹ Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
⁴² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁴³ Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
⁴⁴ Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK.
⁴⁵ Department of Gynecology and Obstetrics, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.
⁴⁶ Alberta Health Services-Cancer Care, Calgary, AB, Canada.
⁴⁷ David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.
⁴⁸ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
⁴⁹ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
⁵⁰ Department of Pathology, University of Gothenburg, Gothenburg, Sweden.
⁵¹ Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
⁵² Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
⁵³ Genetics Service, Fundación Jiménez Díaz, Madrid, Spain.
⁵⁴ Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
⁵⁵ H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁵⁶ Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁵⁷ Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain.
⁵⁸ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵⁹ Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶⁰ Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
⁶¹ Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
⁶² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
⁶³ Section of Gynecologic Oncology Surgery, North Zone, Alberta Health Services, Edmonton, AB, Canada.
⁶⁴ Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
⁶⁵ Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.
⁶⁶ Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
⁶⁷ EUTOPS Institute, University of Innsbruck, Innsbruck, Austria.
⁶⁸ Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁶⁹ Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA.
⁷⁰ Community Health Sciences, University of Calgary, Calgary, AB, Canada.
⁷¹ Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
⁷² Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁷³ Department of Research, Cancer Registry of Norway, Oslo, Norway.
⁷⁴ Computational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁷⁵ Cancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁷⁶ Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
⁷⁷ Division of Acute Disease Epidemiology, South Carolina Department of Health & Environmental Control, Columbia, SC, USA.
⁷⁸ Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
⁷⁹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
⁸⁰ Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA.
⁸¹ Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
⁸² Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁸³ Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
⁸⁴ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
⁸⁵ Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
⁸⁶ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

PMID: 36948887
PMCID: PMC10073933
DOI: 10.1002/cjp2.311

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Martin Köbel et al. J Pathol Clin Res. 2023 May.

. 2023 May;9(3):208-222.

doi: 10.1002/cjp2.311. Epub 2023 Mar 22.

Authors

Affiliations

¹ Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.
² School of Clinical Medicine, UNSW Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
³ Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
⁴ The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
⁵ Pathology Department, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania.
⁶ Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, AB, Canada.
⁷ Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁸ The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, New South Wales, Australia.
⁹ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
¹⁰ Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
¹¹ Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada.
¹² British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, BC, Canada.
¹³ Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
¹⁴ Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
¹⁵ Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
¹⁶ Centre for Cancer Research, The Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia.
¹⁷ Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
¹⁸ Discipline of Obstetrics and Gynaecology, The University of Sydney, Sydney, New South Wales, Australia.
¹⁹ Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
²⁰ Department of Obstetrics and Gynecology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
²¹ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
²² Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
²³ Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
²⁴ Department of Histopathology, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.
²⁵ Department of Metabolism, Digestion and Reproduction, Imperial College London, Hammersmith Hospital, London, UK.
²⁶ Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
²⁷ Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
²⁸ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
²⁹ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
³⁰ QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
³¹ Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
³² Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³³ HM Sanchinarro Centro Integral Oncológico Clara Campal, University Hospital, Madrid, Spain.
³⁴ MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
³⁵ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
³⁶ Department of Propaedeutics, Physical Diagnostics and Dental Physiotherapy, Pomeranian Medical University, Szczecin, Poland.
³⁷ Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany.
³⁸ Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.
³⁹ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁴⁰ Department of Gynecology and Obstetrics, University Hospital of Ulm, Ulm, Germany.
⁴¹ Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
⁴² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁴³ Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
⁴⁴ Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK.
⁴⁵ Department of Gynecology and Obstetrics, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland.
⁴⁶ Alberta Health Services-Cancer Care, Calgary, AB, Canada.
⁴⁷ David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA.
⁴⁸ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
⁴⁹ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
⁵⁰ Department of Pathology, University of Gothenburg, Gothenburg, Sweden.
⁵¹ Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
⁵² Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.
⁵³ Genetics Service, Fundación Jiménez Díaz, Madrid, Spain.
⁵⁴ Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
⁵⁵ H12O-CNIO Lung Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁵⁶ Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁵⁷ Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain.
⁵⁸ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵⁹ Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶⁰ Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
⁶¹ Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
⁶² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, AB, Canada.
⁶³ Section of Gynecologic Oncology Surgery, North Zone, Alberta Health Services, Edmonton, AB, Canada.
⁶⁴ Nottingham Breast Cancer Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
⁶⁵ Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.
⁶⁶ Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
⁶⁷ EUTOPS Institute, University of Innsbruck, Innsbruck, Austria.
⁶⁸ Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁶⁹ Epidemiology, School of Public Health, University of Colorado, Aurora, CO, USA.
⁷⁰ Community Health Sciences, University of Calgary, Calgary, AB, Canada.
⁷¹ Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.
⁷² Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁷³ Department of Research, Cancer Registry of Norway, Oslo, Norway.
⁷⁴ Computational Oncology Group, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
⁷⁵ Cancer Prevention and Control Program, Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁷⁶ Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
⁷⁷ Division of Acute Disease Epidemiology, South Carolina Department of Health & Environmental Control, Columbia, SC, USA.
⁷⁸ Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
⁷⁹ Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
⁸⁰ Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA.
⁸¹ Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA.
⁸² Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁸³ Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
⁸⁴ Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden.
⁸⁵ Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
⁸⁶ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

PMID: 36948887
PMCID: PMC10073933
DOI: 10.1002/cjp2.311

Abstract

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.

Keywords: TP53; clear cell; endometrioid; high-grade serous carcinoma; ovarian cancer; p53; prognosis.

PubMed Disclaimer

Figures

**Figure 1**
(A) p53 IHC patterns. (B) Kaplan‐Meier survival analyses of the three abnormal p53 IHC patterns in HGSC. (C) Kaplan‐Meier survival analyses of abnormal p53 versus normal p53 in EC. (D) Kaplan‐Meier survival analyses of abnormal p53 versus normal p53 in CCC.

**Figure 2**
EC: stage‐stratified Kaplan‐Meier survival analyses. (A) By abnormal versus normal p53 at low FIGO stage (I/II) without residual disease. (B) By grade at low FIGO stage (I/II) without residual disease. (C) Abnormal versus normal p53 at high FIGO stage (III/IV). (D) By combined grade and abnormal versus normal p53 at low FIGO stage (I/II) without residual disease.

**Figure 3**
CCC: stage‐stratified Kaplan‐Meier survival analyses. (A) Abnormal p53 versus normal p53 at low FIGO stage (I/II) without residual disease. (B) Abnormal p53 versus normal p53 at high FIGO stage (III/IV).

**Figure 4**
Association of p53 IHC patterns with *TP53* mRNA expression, including all histotypes.

See this image and copyright information in PMC

References

1. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49–56. - PMC - PubMed
1. Vang R, Levine DA, Soslow RA, et al. Molecular alterations of TP53 are a defining feature of ovarian high‐grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian study. Int J Gynecol Pathol 2016; 35: 48–55. - PMC - PubMed
1. Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2016; 2: 247–258. - PMC - PubMed
1. Rabban JT, Garg K, Ladwig NR, et al. Cytoplasmic pattern p53 immunoexpression in pelvic and endometrial carcinomas with TP53 mutation involving nuclear localization domains: an uncommon but potential diagnostic pitfall with clinical implications. Am J Surg Pathol 2021; 45: 1441–1451. - PubMed
1. Köbel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas. J Pathol 2010; 222: 191–198. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Affiliations

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous